News & Research

Sarcoma Oncology Center is dedicated to offering our patients the best possible solutions for sarcoma care through our multimodal treatment approach that includes access to the most recent and updated clinical trials.

Please contact us if you have any questions or would like more information. We offer patients comprehensive information to help them make informed decisions.

News

If you’re interested in learning more about sarcoma, see the latest news regarding sarcoma treatment and clinical drug trials below.

LadRx’s Aldoxorubicin
Oral Presentation of LadRx’s Aldoxorubicin Phase 2b Clinical Trial in Soft Tissue Sarcoma highlighted in The Lancet Oncology
Dr. Sant Chawla’s featured article in The Lancet Oncology journal in 2013 on ground-breaking work in Giant Cell Tumors
CytRx Announces Overall Survival Results from Its Global Phase 2b Clinical Trial of Aldoxorubicin in Soft Tissue Sarcoma
Sarcoma Oncology Center Leverages BostonGene’s AI-driven Molecular and Immune Profiling Platform to Identify Novel Treatment Options for Patients with Advanced Cancers

Research

Below are links to information regarding clinical trial results and to other sources you may find useful when researching sarcomas.

Results of an international Randomized Phase III Trial of the mammalian target of Rapamycin Inhibitor Ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy
Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma
Sarcoma information from the American Cancer Society
Educational resources from the Sarcoma Alliance
ANTICANCER RESEARCH – International Journal of Cancer Research and Treatment, From Mendel to Gene Therapy
SAINT: A phase I/expanded phase II study using safe amounts of Ipilimumab, Nivolumab and Trabectedin as first-line treatment of advanced soft tissue sarcoma
Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas
Early-stage CCNG1+ HR+ HER2+ invasive breast carcinoma in older women: current treatment and future perspectives for DeltaRex-G, a CCNG1 inhibitor
Three year results of Blessed: Expanded access for DeltaRex-G for an intermediate size population with advanced pancreatic cancer and sarcoma (NCT04091295) and individual patient use of DeltaRex-G for solid malignancies

Contact Sarcoma Oncology Center for More Information

Sarcoma Oncology Center is here to help you through this treatment journey. If you would like more information on sarcoma news & research, please contact us at 310-552-9999 or request an appointment online.